

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT												
NATURE OF CONVEYANCE:	ASSIGNMENT												
CONVEYING PARTY DATA													
<table border="1"> <thead> <tr> <th>Name</th> <th>Execution Date</th> </tr> </thead> <tbody> <tr> <td>Antonin de Fougerolles</td> <td>10/03/2012</td> </tr> <tr> <td>Atanu Roy</td> <td>10/15/2012</td> </tr> <tr> <td>Stephane Bancel</td> <td>10/03/2012</td> </tr> </tbody> </table>		Name	Execution Date	Antonin de Fougerolles	10/03/2012	Atanu Roy	10/15/2012	Stephane Bancel	10/03/2012				
Name	Execution Date												
Antonin de Fougerolles	10/03/2012												
Atanu Roy	10/15/2012												
Stephane Bancel	10/03/2012												
RECEIVING PARTY DATA													
<table border="1"> <tr> <td>Name:</td> <td>modeRNA Therapeutics</td> </tr> <tr> <td>Street Address:</td> <td>161 First Street</td> </tr> <tr> <td>Internal Address:</td> <td>1st Floor</td> </tr> <tr> <td>City:</td> <td>Cambridge</td> </tr> <tr> <td>State/Country:</td> <td>MASSACHUSETTS</td> </tr> <tr> <td>Postal Code:</td> <td>02142</td> </tr> </table>		Name:	modeRNA Therapeutics	Street Address:	161 First Street	Internal Address:	1st Floor	City:	Cambridge	State/Country:	MASSACHUSETTS	Postal Code:	02142
Name:	modeRNA Therapeutics												
Street Address:	161 First Street												
Internal Address:	1st Floor												
City:	Cambridge												
State/Country:	MASSACHUSETTS												
Postal Code:	02142												
PROPERTY NUMBERS Total: 1													
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> </tr> </thead> <tbody> <tr> <td>Application Number:</td> <td>13644072</td> </tr> </tbody> </table>		Property Type	Number	Application Number:	13644072								
Property Type	Number												
Application Number:	13644072												
CORRESPONDENCE DATA													
<p>Fax Number: 9784488721 <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i></p> <p>Email: kcorbett@dtwardlaw.com Correspondent Name: DTWARD, PC Address Line 1: 292 Main Street Address Line 2: Suite 2 Address Line 4: Groton, MASSACHUSETTS 01450</p>													
ATTORNEY DOCKET NUMBER:	2030.1009US/M009.10												
NAME OF SUBMITTER:	Kristin Corbett												
<p>Total Attachments: 3 source=Assignment#page1.tif source=Assignment#page2.tif source=Assignment#page3.tif</p>													

CH \$40.00 13644072

ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to modeRNA Therapeutics, having a place of business at 161 First Street, 1st Floor, Cambridge, MA 02142, for itself and its successors, transferees, and assigns (herein "ASSIGNEE") the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- Application No. 13/644,072, entitled "MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF", filed October 3, 2012, which claims priority from US Provisional Application No. 61/542,533, filed October 3, 2011, entitled "MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF".

2. The entire worldwide right, title, and interest in and to:
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to sue for and recover damages for past acts of infringement, whether based on any patents listed herein, patents issuing from applications listed herein or provisional rights from any patent application listed herein.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

Title: MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC
ACIDS, AND USES THEREOF
Filed: October 3, 2012
PCT Application No: 13/644,072

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

INVENTOR acknowledges the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Date Oct 3, 2012 Signature 
Name Antonin de Fougerolles

Date 10/15/2012 Signature 
Name Atanu Roy

Date _____ Signature _____
Name Jason P. Schrum

Date _____ Signature _____
Name Suhaib Siddiqi

Title: MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC
ACIDS, AND USES THEREOF
Filed: October 3, 2012
PCT Application No: 13/644,072

Date _____ Signature _____
Name Paul Hatala

Date 10/3/2012 Signature S. Bancel
Name Stephane Bancel